Back to results
US 10,870,673 B2Granted
β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment
AssigneeAtea Pharmaceuticals, Inc.
InventorsJean-Pierre Sommadossi, Adel Moussa
Life of this patent
Estimating the term…
Abstract
A compound of the structure: or a pharmaceutically acceptable salt or composition thereof for the treatment of a host infected with or exposed to an HCV virus or other disorders more fully described herein.
Claims34
A compound of the formula
- or a pharmaceutically acceptable salt thereof.
A compound of the formula
- or a pharmaceutically acceptable salt thereof.
A compound of the formula:
- or a pharmaceutically acceptable salt thereof, wherein the compound is at least 90% free of the opposite phosphorus R-enantiomer.
A pharmaceutical composition comprising an effective therapeutic amount of a compound of the formula
- or a pharmaceutically acceptable salt thereof in a pharmaceutically acceptable carrier, wherein the compound is at least 90% free of the opposite phosphorus R-enantiomer.
Dependencies are inferred from the claim text.